HillCo Health
The November issue of the Oncology Business Review (OBR) prominently features HillCo Health's article on "Commercialization of Oncology Medicines and Federal Policy:
Why Technology Transfer Offices Should Increase Their Activities on Coverage
and Reimbursement Issues." (See http://www.oncbiz.com/
Cancer is the number one killer in people younger than 85 years of age and accounts for an estimated $72.1 billion – just under 5 percent of U.S. spending for all medical treatment. In addition, cancer deaths costs the U.S. an estimated $115.8 billion in lost productivity and when including the value of caregiving and household duties lost, as well as regular wage earning, the cost of cancer mortality more than double to $232.4 billion.
The bio-pharmaceutical industry is partnering with cancer centers and offices of technology transfer/commercialization on oncology R&D to tackle cancer and bring new therapies to market. If successful, the oncology bio-pharmaceutical market by 2012, is scheduled to grow at a “compound annual rate of 12% to 15% to reach $75 to $80 billion in global sales.” Depending on the licensing agreements and sales milestones between technology transfer offices and bio-pharmaceutical companies, universities and/or cancer centers would benefit in the form of royalties.
However, as a consequence of increased Congressionally approved mandates on the U.S. Food and Drug Administration, legislative enacted drug and device reimbursement reforms, and the growing influence of the estimated $1 Trillion government-run healthcare systems – e.g., Medicare, Medicaid, Veterans Affairs, Indian Health Services, Federal Employee Health Programs, State Employee Health Programs – oncology medicines and technology are facing reimbursement challenges that could affect access, sales and royalty projections.
As such, technology transfer/commercialization offices with oncology portfolios should expand their healthcare policy engagement to include coverage and reimbursement capabilities.
HillCo Health's article is featured in the lead journal for the oncology healthcare sub-sector. OBR is a primary information resource dedicated exclusively to the business of oncology. OBR provides instantaneous oncology news, provocative journalism, topical discussion, and a place to track performance of oncology products, companies, and people.
HillCo Health has a number of former U.S. Department of Health and Human Services staffers with extensive experience at and working with the Centers for Medicare and Medicaid Services, Food and Drug Administration, Agency for Healthcare Research and Quality, and state health programs.
HillCo Health Team
Grant Bagley M.D. J.D.
Former Director, Coverage and Analysis Group, CMS
Former Medical Officer, Office of the Commissioner, FDA
Marc Samuels J.D., M.P.H.
Former White House Office of Domestic Policy Aide,
Former Gubernatorial Health Policy Advisor, TX Health and Human Services Commission
Michael Beebe
Former Director, AMA CPT and RUC
Doran Edwards, M.D.
Former Medical Director, Palmetto G.B.A. and PDAC (Pricing, Data, Analysis Coding) Contractor Chief Medical Officer
Caleb DesRosiers, J.D., M.P.A.
Former HHS/CMS Special Assistant,
Former Policy Director, Hoffmann-La Roche Inc., Pfizer Inc.
Former Health Policy Advisor, Massachusetts Speaker’s Office
Alissa Williams Pereira M.P.H.
Former Legislative Analyst, Schering Plough Corporation
Danielle Pambianco M.P.H
Former Healthcare Analyst, Altarum Institute
HillCo Health is a division of HillCo Partners - www.hillcopartners - a government relations firm located in Austin, Texas.
Photo:
http://www.prlog.org/
